Bifunctional Alpha-Synuclein Degraders via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases associated with α-synuclein overexpression or aggregation, such as Parkinson's Disease and Alzheimer's Disease, face challenges due to the difficulty in targeting and modulating α-synuclein effectively, as small molecules struggle to disrupt protein-protein interactions and leverage E3 ubiquitin ligase substrate specificity.
Innovation Solution
Development of bifunctional compounds, known as PROTACs, that recruit target proteins to E3 ubiquitin ligases for degradation, comprising an E3 ubiquitin ligase binding moiety and a target protein binding moiety, utilizing linkers to facilitate the degradation of α-synuclein and other proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If small molecules are used to target α-synuclein, then the simplicity of small molecule administration is maintained, but the ability to effectively disrupt protein-protein interactions and modulate α-synuclein is insufficient
Solution Approach 1:
The patent merges a small molecule E3 ligase binder with a protein target binder into a single bifunctional compound. This combination allows the compound to leverage both the ease of small molecule administration and the specificity of protein-protein interaction disruption, resolving the contradiction between simplicity and effectiveness.
Solution Approach 2:
The bifunctional compound acts as an intermediary that recruits endogenous proteins to an E3 ubiquitin ligase. The E3 ligase binding moiety serves as the anchor that mediates the interaction between the small molecule and the protein degradation machinery, enabling effective target modulation while maintaining administrative simplicity.
2Reliability
If E3 ubiquitin ligases are targeted to achieve substrate specificity, then the specificity for certain protein substrates is improved, but the difficulty of developing ligands that disrupt protein-protein interactions increases
Solution Approach 1:
The ligand is segmented into two distinct functional moieties: an E3 ligase binding moiety that provides substrate specificity and a target protein binding moiety that recognizes the disease target. This segmentation allows each moiety to be optimized independently, reducing the overall complexity of ligand development while maintaining high specificity.
Solution Approach 2:
The bifunctional compound design provides multi-functionality by combining target recognition, E3 ligase recruitment, and ubiquitination induction in a single molecule. This universal approach can be applied to various protein targets by simply changing the target-binding moiety while retaining the E3 ligase recruitment functionality, thereby reducing development complexity across different indications.
3Reliability
If bifunctional compounds are developed to recruit target proteins to E3 ligases, then the degradation and inhibition of α-synuclein is improved, but the structural complexity of the compound increases
Solution Approach 1:
Different regions of the bifunctional compound have specialized local qualities: the E3 ligase binding moiety is optimized for high-affinity binding to the ligase, the linker provides appropriate spacing and flexibility, and the target protein binding moiety is optimized for target recognition. This local optimization allows effective degradation while managing structural complexity through functional specialization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds effectively degrade and inhibit α-synuclein, providing therapeutic potential for diseases like Parkinson's Disease and Alzheimer's Disease by modulating protein levels and ameliorating disease conditions.
Implementation Method 1
bifunctional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation
Implementation Method 2
targeted protein degradation, proteolysis
Data Source
AI summary
The present disclosure relates to bifunctional compounds, which find utility as modulators of α-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon. Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.